Related Experiment Video
Updated: Mar 31, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
miR-138-Mediated Regulation of KINDLIN-2 Expression Modulates Sensitivity to Chemotherapeutics
Khalid Sossey-Alaoui1, Edward F Plow2
1Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. sosseyk@ccf.org.
Unlabelled:
Prostate cancer is the second leading cause of cancer-related death in men, second only to lung cancer, mainly due to disease reoccurrence as a result to lack of response to androgen deprivation therapies (ADT) after castration. Patients with metastatic castration-resistant prostate cancer (mCRPC) have very limited treatment options, with docetaxel as the first-line standard of care, for which resistance to this chemotherapeutic ultimately develops. Therefore, finding ways to sensitize tumors to chemotherapies and to limit chemoresistance provides a viable strategy to extend the survival of mCRPC patients. This study investigated the role of Kindlin-2 (FERMT2/K2), a member of the Kindlin family of FERM domain proteins and key regulators of the adhesive functions mediated by integrin, in the sensitization of mCRPC to chemotherapeutics. Loss of K2, which is overexpressed in prostate cancer cells derived from mCRPC tumors, compared with those cells derived from androgen-dependent tumors, significantly enhanced apoptosis and cell death of docetaxel-treated PC3 cells. Furthermore, it was determined that K2-mediated sensitization to docetaxel treatment is the result of inhibition of β1-integrin signaling. Finally, miR-138 specifically targeted K2 and inhibited its expression, thereby regulating a miR-138/K2/β1-integrin signaling axis in mCRPC that is critical for the modulation of sensitivity to chemotherapeutics. Thus, these data identify a novel signaling axis where K2 in combination with chemotherapeutics provides a new target for the treatment of mCRPC.
Implications:
Targeted inhibition of Kindlin-2 in combination with chemotherapy represents an effective treatment option for mCRPC.
Insights
Targeting Kindlin-2 (K2) can sensitize metastatic castration-resistant prostate cancer (mCRPC) to chemotherapy. Inhibiting K2 enhances docetaxel effectiveness by blocking beta1-integrin signaling, offering a new treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Prostate cancer recurrence and resistance to androgen deprivation therapies (ADT) limit treatment options for metastatic castration-resistant prostate cancer (mCRPC).
- Docetaxel is the first-line treatment for mCRPC, but resistance eventually develops, necessitating strategies to improve chemotherapy sensitivity and overcome resistance.
- Kindlin-2 (K2) is a protein that regulates integrin function and is overexpressed in mCRPC cells compared to androgen-dependent prostate cancer cells.
Purpose of the Study:
- To investigate the role of Kindlin-2 (K2) in sensitizing mCRPC to chemotherapeutics.
- To elucidate the molecular mechanisms by which K2 influences chemotherapy response in mCRPC.
- To identify novel therapeutic targets for mCRPC treatment.
Main Methods:
- Studied the effect of K2 knockdown on docetaxel-induced apoptosis and cell death in PC3 cells (mCRPC model).
- Investigated the role of beta1-integrin signaling in K2-mediated sensitization to docetaxel.
- Analyzed the regulatory relationship between miR-138 and K2 expression in mCRPC.
Main Results:
- Loss of K2 significantly enhanced apoptosis and cell death in docetaxel-treated PC3 cells.
- K2-mediated sensitization to docetaxel was linked to the inhibition of beta1-integrin signaling.
- miR-138 was identified as a direct regulator of K2, targeting its expression and influencing the miR-138/K2/beta1-integrin signaling axis.
Conclusions:
- A novel signaling axis involving miR-138, K2, and beta1-integrin plays a critical role in modulating chemotherapy sensitivity in mCRPC.
- Targeted inhibition of K2, in combination with chemotherapy, presents a promising therapeutic strategy for mCRPC.
More Related Videos
Related Concept Videos
01:15Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
02:38Mitogens and the Cell Cycle
01:22MicroRNAs
01:22MicroRNAs